The mGlu5 receptor agonist CHPG stimulates striatal glutamate release
- 1 November 2000
- journal article
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 11 (16) , 3611-3614
- https://doi.org/10.1097/00001756-200011090-00042
Abstract
The intrastriatal perfusion of the selective metabotropic glutamate (mGlu)5 receptor agonist (RS)-2-chloro-5-hydroxy-phenylglycine (CHPG, 1000 microM) significantly increased (approximately + 100%, p < 0.05) glutamate extracellular levels with respect to basal values. The potentiating effect of CHPG was prevented by the selective mGlu5 receptor antagonist 2-methyl-6(phenyl-ethynyl)-pyridine (MPEP, 250 microM)) and by the adenosine A2A receptor antagonist SCH 58261 (2 mg/kg, i.p.). The results show that mGlu5 receptors are involved in the regulation of striatal glutamate release and suggest an involvement of adenosine A2A receptors in mGlu5 receptor-mediated effects.Keywords
This publication has 6 references indexed in Scilit:
- Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative DiseasesAnnals of the New York Academy of Sciences, 1999
- Pharmacological agents acting at subtypes of metabotropic glutamate receptorsPublished by Elsevier ,1999
- The intrastratial injection of an adenosine A2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's diseaseBrain Research, 1999
- Group I mGlu receptors potentiate synaptosomal [3H]glutamate release independently of exogenously applied arachidonic acidNeuropharmacology, 1999
- Metabotropic Glutamate Agonist-Induced Rotation: A Pharmacological, FOS Immunohistochemical, and [14C]-2-Deoxyglucose Autoradiographic StudyJournal of Neuroscience, 1997
- Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: An in situ hybridization study in adult and developing ratJournal of Comparative Neurology, 1992